Pharmaceutical Stability and Storage Services Market Report 2026

The pharmaceutical stability and storage services market size has grown strongly in recent years. It will grow from $2.81 billion in 2025 to $2.99 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to strict pharmaceutical regulatory requirements, growth in global drug production, expansion of biologics manufacturing, need for shelf-life validation, increasing clinical trial volumes.

The pharmaceutical stability and storage services market size is expected to see strong growth in the next few years. It will grow to $3.78 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to growth in biologics and cell therapies, increasing pharmaceutical outsourcing, expansion of global cold chain infrastructure, rising vaccine production, stronger regulatory scrutiny on drug stability. Major trends in the forecast period include rising demand for regulatory-compliant storage, increasing outsourcing of stability testing services, growing need for cold chain and cryogenic storage, expansion of stability services for biologics, higher focus on long-term drug quality assurance.

The rising number of novel drug approvals is expected to drive the growth of the pharmaceutical stability and storage services market in the coming years. A novel drug is a pharmaceutical compound that has been newly developed and has not been previously approved for use or marketed. The increase in novel drug approvals is attributed to advancements in biotechnology, which enable the discovery of new compounds, along with improved regulatory processes that support faster and more efficient drug development. The growth in novel drug approvals fuels the demand for pharmaceutical stability and storage services, ensuring optimal conditions, regulatory compliance, and effective shelf-life management. For example, in October 2023, according to the U.S. Food and Drug Administration (FDA), a US-based federal agency responsible for protecting public health, the FDA approved 37 novel drugs in 2022, followed by 50 in 2024, advancing treatments in areas such as cancer, rare diseases, neurology, infections, and conditions like schizophrenia, pain, and Alzheimer's. Consequently, the increasing number of novel drug approvals drives the growth of the pharmaceutical stability and storage services market.

Major companies operating in the pharmaceutical stability and storage services market are concentrating on developing technologically advanced solutions, such as cryogenic storage suites, to improve the preservation of temperature-sensitive pharmaceutical products. Cryogenic storage suites are specialized facilities that maintain extremely low temperatures, typically below -150°C, to safeguard temperature-sensitive biological and pharmaceutical materials, including cell therapies, vaccines, and biologics. For example, in December 2024, Astoriom, a UK-based stability and biospecimen storage company, unveiled a cryogenic storage suite at its Tramore facility in County Waterford, Ireland, representing a significant enhancement of its capabilities for biological sample storage. This advanced suite is designed to address the growing need for safe, long-term preservation of biological materials, ensuring their viability over extended periods. The storage system offers precise temperature control down to -196°C, extensive storage capacity, ISO 9001 certification for regulatory compliance, and sophisticated security measures, including access controls and monitoring systems.

In January 2024, Alcami Corporation, a US-based contract development and manufacturing organization (CDMO), acquired Pacific Pharmaceutical Services, Inc. for an undisclosed amount. Through this acquisition, Alcami seeks to broaden its pharmaceutical storage and service capabilities, improve bi-coastal service coverage, and enhance its capacity to manage pre-clinical and clinical materials with greater security and multi-location resilience. Pacific Pharmaceutical Services, Inc. is a US-based company providing pharmaceutical clinical distribution services, offering stability and storage solutions, including a range of cGMP-compliant storage conditions from controlled room temperature to cryogenic temperatures.

Major companies operating in the pharmaceutical stability and storage services market are SGS S.A., Eurofins Scientific SE, Intertek Group plc, Catalent Inc., Almac Group, Alcami Corporation, Reading Scientific Services Ltd., Charles River Laboratories, Element Materials Technology Inc., Precision Stability Storage, Roylance Stability Storage Limited, BioLife Solutions Inc., Alloga UK Ltd., Auriga Research Private Limited, Q Laboratories Inc., ALS Limited, Lucideon Limited, Cencora Inc., PCI Pharma Services, DHL Life Sciences & Healthcare.

North America was the largest region in the pharmaceutical stability and storage services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical stability and storage services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical stability and storage services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the pharmaceutical stability and storage services market by increasing the cost of imported temperature-control equipment, monitoring systems, storage containers, and facility components used in compliant storage environments. These impacts have been most pronounced in cryogenic and refrigerated storage segments, particularly in north america and europe where equipment sourcing is globally diversified. Asia-pacific service providers have faced capital cost pressures due to import dependencies. However, tariffs have encouraged domestic manufacturing of storage infrastructure and localized service expansion, improving supply security and operational resilience.

The pharmaceutical stability and storage services market research report is one of a series of new reports that provides pharmaceutical stability and storage services market statistics, including pharmaceutical stability and storage services industry global market size, regional shares, competitors with a pharmaceutical stability and storage services market share, detailed pharmaceutical stability and storage services market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical stability and storage services industry. This pharmaceutical stability and storage services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical stability and storage services are specialized services designed to ensure that pharmaceutical products, including drugs, medications, and vaccines, retain their quality, efficacy, and safety over time. These services involve controlled storage environments for drugs, performing stability studies to track chemical, physical, and microbiological changes, and ensuring adherence to regulatory standards.

The primary pharmaceutical stability and storage services encompass stability and storage. Stability services evaluate how pharmaceutical products preserve their quality, potency, and safety under varying environmental conditions over time. These services are applied to a range of products including tablets, capsules, injectable solutions, oral suspensions, combination products, and more, and can involve both small and large molecules. They are offered through in-house and outsourcing models and are utilized by biopharmaceutical companies, contract manufacturing organizations, contract research organizations, and others.

The pharmaceutical stability and storage services market consists of revenues earned by entities by providing services such as photostability testing, cold chain management, disaster recovery and backup storage. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmaceutical stability and storage services market also includes sales of stability chambers, cryogenic storage systems, cold storage units and automated sample management systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.